Perbak Capital Partners LLP Boosts Illumina Stake by 79.5%

Hedge fund increases position in life sciences company during third quarter

Mar. 14, 2026 at 9:06am

Got story updates? Submit your updates here. ›

Perbak Capital Partners LLP, a hedge fund, has increased its stake in Illumina, Inc. (NASDAQ:ILMN) by 79.5% during the third quarter, according to a recent filing with the Securities and Exchange Commission. The firm now owns 32,315 shares of the life sciences company's stock, valued at $3,069,000.

Why it matters

Illumina is a leading provider of DNA sequencing and array-based technologies, playing a crucial role in the life sciences industry. This investment by Perbak Capital Partners LLP suggests the hedge fund sees growth potential in Illumina's business and technology.

The details

Perbak Capital Partners LLP purchased an additional 14,315 shares of Illumina during the third quarter, bringing its total position to 32,315 shares. The hedge fund's investment in Illumina now accounts for approximately 0.5% of its overall portfolio.

  • Perbak Capital Partners LLP increased its stake in Illumina during the third quarter of 2026.

The players

Perbak Capital Partners LLP

A hedge fund that has increased its investment in Illumina, Inc.

Illumina, Inc.

A global life sciences company that develops and markets integrated systems for the analysis of genetic variation and function.

Got photos? Submit your photos here. ›

The takeaway

Perbak Capital Partners LLP's significant increase in its Illumina stake suggests the hedge fund sees long-term growth potential in the life sciences company's technology and market position.